|
rs104893626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs773862672
|
|
|
0.010 |
GeneticVariation |
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs77375493
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
|
23558526 |
2013 |
|
rs121917887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs201216664
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs10009228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A SNP in the alpha9 subunit, the G allele of rs10009228 (alpha9, A>G) shows a significant trend in the combined cohort, indicating that this allele constitutes a risk factor for neoplastic progression.
|
22406075 |
2012 |
|
rs9282861
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs1042028
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs752021744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression.
|
22684718 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
|
23533235 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
|
23533235 |
2013 |
|
rs1057519710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of a 17-cm malignant GIST in the index patient revealed that it was hemi/homozygous for the germline D820Y mutation, indicating loss of the remaining wild-type KIT allele with tumor progression.
|
16327443 |
2005 |
|
rs1284806277
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1285136498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs1418810723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs4986791
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not.
|
21920464 |
2011 |
|
rs1057519771
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHMFL-ABL-039 has demonstrated greater efficacies than Imatinib regarding to the anti-proliferation, inhibition of the signaling pathway, arrest of cell cycle progression, induction of apoptosis in vitro and suppression of the tumor progression in vivo in the native and V299L mutated BCR-ABL kinase-driven cells/xenograft models.
|
30894066 |
2019 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
|
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression.
|
26577492 |
2016 |